2019
“I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes
Commissariat PV, Harrington KR, Whitehouse AL, Miller KM, Hilliard ME, Van Name M, DeSalvo DJ, Tamborlane WV, Anderson BJ, DiMeglio LA, Laffel LM. “I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes. Pediatric Diabetes 2019, 21: 377-383. PMID: 31808586, PMCID: PMC7830825, DOI: 10.1111/pedi.12956.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlycemic controlDiabetes burdenSecondary caregiversEmotional burdenChildren's glycemic controlYoung childrenCare of childrenAge 5.2Parents' perceptionsCaregivers' knowledgeClinical centersSemi-structured qualitative interviewsDiabetesDiabetes educationParental burdenHealthcare providersAge groupsInsulin pumpParents' burdenT1DChildren's qualityChild's diabetesParents' knowledgeParents' confidence
2018
Persistence of abnormalities in white matter in children with type 1 diabetes
Fox LA, Hershey T, Mauras N, Arbeláez AM, Tamborlane WV, Buckingham B, Tsalikian E, Englert K, Raman M, Jo B, Shen H, Reiss A, Mazaika P, for the Diabetes Research in Children Network (DirecNet). Persistence of abnormalities in white matter in children with type 1 diabetes. Diabetologia 2018, 61: 1538-1547. PMID: 29654376, PMCID: PMC5991628, DOI: 10.1007/s00125-018-4610-6.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkersBlood GlucoseCase-Control StudiesChildChild DevelopmentChild, PreschoolCognitive DysfunctionDiabetes Mellitus, Type 1Diffusion Tensor ImagingFemaleGlycated HemoglobinHumansLeukoencephalopathiesLongitudinal StudiesMagnetic Resonance ImagingMalePrognosisRisk FactorsTime FactorsUnited StatesConceptsType 1 diabetesNon-diabetic childrenWhite matter microstructureWhite matterAltered white matter developmentContinuous glucose monitoring (CGM) profilesFractional anisotropyConclusions/interpretationThese resultsPersistence of abnormalitiesLongitudinal observational studyWhite matter growthYoung childrenWhite matter developmentMild cognitive deficitsHigher fractional anisotropyDiabetes groupClinical centersMethodsOne hundredObservational studyDiabetesInterpretationThese resultsCognitive deficitsHyperglycaemiaDiabetes researchAdverse effects
2016
Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care 2016, 39: 555-562. PMID: 26884472, PMCID: PMC4806770, DOI: 10.2337/dc15-1606.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAdolescentBlood GlucoseChildChild, PreschoolCohort StudiesCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugDouble-Blind MethodDrug-Related Side Effects and Adverse ReactionsFemaleGlucagonHumansHypoglycemiaInjections, IntramuscularInsulinMaleNauseaPowdersConceptsIntramuscular glucagonType 1 diabetesIntranasal dosesIntranasal glucagonYounger cohortsWeight-based doseMin of dosingTreatment of hypoglycemiaDose-response relationshipTransient nauseaDl riseSevere hypoglycemiaGlucagon levelsIntranasal doseClinical centersPlasma glucosePharmacodynamic studiesHospital settingGlucagon preparationPotential efficacyGlucagonType 1Adverse effectsCohortAge range
2015
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2015, 39: 264-270. PMID: 26681725, PMCID: PMC4722945, DOI: 10.2337/dc15-1498.Peer-Reviewed Original ResearchConceptsInsulin-induced hypoglycemiaType 1 diabetesIntramuscular glucagonIntranasal glucagonSevere hypoglycemiaPlasma glucoseCrossover noninferiority trialTreatment of hypoglycemiaLoss of consciousnessReal-world managementDosing visitsGlucagon responseIntravenous insulinNoninferiority studyGlucagon administrationClinical centersFacial discomfortNoninferiority trialHospital settingGlucagon preparationHypoglycemiaTherapeutic insulinGlucagonType 1Mean time
2013
Pediatric Diabetes Consortium Type 1 Diabetes New Onset (NeOn) Study: factors associated with HbA1c levels one year after diagnosis
Redondo MJ, Connor CG, Ruedy KJ, Beck RW, Kollman C, Wood JR, Buckingham B, Klingensmith GJ, Silverstein J, Tamborlane WV, Consortium F. Pediatric Diabetes Consortium Type 1 Diabetes New Onset (NeOn) Study: factors associated with HbA1c levels one year after diagnosis. Pediatric Diabetes 2013, 15: 294-302. PMID: 23889707, PMCID: PMC3858510, DOI: 10.1111/pedi.12061.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood Glucose Self-MonitoringChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisFemaleFollow-Up StudiesGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInfantInsulinMaleNuclear FamilyProspective StudiesSocioeconomic FactorsUnited StatesConceptsPediatric Diabetes ConsortiumLower insulin requirementsBody mass indexDiabetic ketoacidosisInsulin requirementsWhite raceNon-Hispanic white raceDeterminants of hemoglobinOnset of T1DType 1 diabetesLevels one yearHigher socioeconomic statusFirst yearPositive autoantibodiesSD HbA1cNew onsetMass indexBlood glucoseClinical centersDiabetes physiciansPrivate health insuranceTanner stageNumber of visitsFrequent SMBGIntervention studies
2012
Accuracy and Precision of the Axis-Shield Afinion Hemoglobin A1c Measurement Device
Wood JR, Kaminski BM, Kollman C, Beck RW, Hall CA, Yun JP, Cengiz E, Haller MJ, Hassan K, Klingensmith GJ, Tamborlane WV. Accuracy and Precision of the Axis-Shield Afinion Hemoglobin A1c Measurement Device. Journal Of Diabetes Science And Technology 2012, 6: 380-386. PMID: 22538150, PMCID: PMC3380782, DOI: 10.1177/193229681200600224.Peer-Reviewed Original ResearchConceptsNational Glycohemoglobin Standardization ProgramPediatric practice settingsWhole blood samplesBlood samplesHigh-performance liquid chromatographyPractice settingsDCA deviceHigher A1C levelsBoronate affinity methodMeasurement of hemoglobinA1c levelsDiabetes mellitusClinic sitesA1C resultsClinical centersAfinionCapillary bloodPatient samplesCentral laboratoryConsortium sitesA1CImmunoassay methodStandardization ProgramHPLC methodAbsolute difference
2005
Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study
Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW, Chase P, Fox LA, Wilson DM, Tsalikian E. Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatric Diabetes 2005, 6: 13-16. PMID: 15787896, DOI: 10.1111/j.1399-543x.2005.00088.x.Peer-Reviewed Original ResearchConceptsDCA 2000Central laboratory valuesHbA1c valuesClinical centersLaboratory valuesComplications Trial/EpidemiologyType 1 diabetes mellitusMean differenceDiabetes researchBaseline HbA1c levelsHemoglobin A1c levelsCentral laboratoryOutpatient clinical trialAdditional blood samplesCentral laboratory methodHbA1c levelsA1c levelsDiabetes mellitusDiabetes practiceDiabetes controlDiabetes InterventionsClinical trialsSame visitBlood samplesReference standard